A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma

Liu, Liwei; Zhang, Qiuhao; Guo, Wenna; Qian, Kun; Wang, Qiang

doi:10.1155/2016/6945304

Cited by 5 publications

(11 citation statements)

References 32 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhile, a comparison of the five-DNA methylation signature with other known prognostic biomarkers showed that it had distinctly higher sensitivity and specificity in the outcome prediction of OSC. The five-mRNA signature identified in a previous study [ 29 ] also had high accuracy surpassed only by the five-DNA methylation signature. However, these five mRNAs were completely different from the genes that corresponded to the five DNA methylation sites in this study.…”

Section: Discussionmentioning

confidence: 79%

“…All these results inspiringly revealed that the five-DNA methylation signature provided better stability and reliability in predicting the OS of patients with OSC and was a superior predictor. Additionally, the expression of the genes corresponding to the five DNA methylation sites and genes in the five-mRNA signature [ 29 ] whose accuracy is second only to the five-DNA methylation signature were also analyzed. And the results demonstrated that the latter genes had higher fold changes in the comparison of high- and low-risk patients, and no difference was noted in the expression of almost all the former five genes in this study (Additional file 1 : Figure S6).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Guo

Zhu

et al. 2018

Clin Epigenet

Self Cite

View full text Add to dashboard Cite

BackgroundOvarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options.ResultsThe methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers.ConclusionsThis five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.Electronic supplementary materialThe online version of this article (10.1186/s13148-018-0574-0) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Resultsmentioning

confidence: 99%

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Guo

Zhu

et al. 2018

Clin Epigenet

Self Cite

View full text Add to dashboard Cite

show abstract

“…To achieve good curative effect, the most important prerequisite is accurate tumor staging in the patients with ovarian cancer. A number of studies have used gene expression for the prognosis of OSC, which exhibit high sensitivity and specificity, and may be clinically significant (27,28). The G2 and G3 grades are crucial indicators for prognosis in OSC as the metastatic rate of ovarian cancer is closely associated with histological grade.…”

Section: Discussionmentioning

confidence: 99%

Identification of a 3‑mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3

Zhou

Wang

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

The use of mRNAs as biomarkers serves to diagnose, treat, as well as aid the prognosis of cancer. The present study involved an analysis of mRNAs in the cell cycle at the G2 and G3 tumor grades for the prognosis of ovarian serous cystadenocarcinoma (OSC) using 364 clinical samples (G2:G3=42:322). Statistics aided the identification of NPFFR2, XPNPEP2 and CELA3B; the 3-mRNA model that allows for classification of patients into high- and low-risk groups using a median value of 0.9580745. The rates of survival varied (P=0.00149) and the independent detection of stratification of the risk of this disease was validated with success using the 3-mRNA signature, which was demonstrated to be more successful than the weight model. This approach was revealed to provide the prognosis of grade G2 and G3 in patients with OSC compared with factors used traditionally. Compared with traditional factors, this 3-mRNA model was demonstrated to be the only and independent prognostic factor for patients with G2 and G3 stage OSC. A literature survey was also performed in the present study in order to assess the role of the 3 genes and indirectly prove their effectiveness. The establishment of this new genetic model will enhance prospective prognosis and treatment for patients with OSC.

show abstract

“…We compared the performance of our 11-gene signature with a recently published 5-gene signature for prognosis of ovarian serous CAC [15]. A multivariate Cox regression analysis was conducted with the 5 genes on the same 100 training sets as described above for our inner validation.…”

Section: Methodsmentioning

confidence: 99%

“…We then used nine independent HGSOC datasets to validate the prognostic scoring system and signature's performance. Moreover, in comparison with an existing 5-gene expression signature for ovarian serous cystadenocarcinoma (CAC) [15], we showed that our signature was superior in determining overall survival for this type of epithelial ovarian carcinoma.…”

Section: Introductionmentioning

confidence: 91%

A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer

Zhao

Yang

Jin

et al. 2019

Journal of Oncology

View full text Add to dashboard Cite

The objective of this research was to develop a robust gene expression-based prognostic signature and scoring system for predicting overall survival (OS) of patients with high-grade serous ovarian cancer (HGSOC). Transcriptomic data of HGSOC patients were obtained from six independent studies in the NCBI GEO database. Genes significantly deregulated and associated with OS in HGSOCs were selected using GEO2R and Kaplan–Meier analysis with log-rank testing, respectively. Enrichment analysis for biological processes and pathways was performed using Gene Ontology analysis. A resampling/cross-validation method with Cox regression analysis was used to identify a novel gene expression-based signature associated with OS, and a prognostic scoring system was developed and further validated in nine independent HGSOC datasets. We first identified 488 significantly deregulated genes in HGSOC patients, of which 232 were found to be significantly associated with their OS. These genes were significantly enriched for cell cycle division, epithelial cell differentiation, p53 signaling pathway, vasculature development, and other processes. A novel 11-gene prognostic signature was identified and a prognostic scoring system was developed, which robustly predicted OS in HGSOC patients in 100 sampling test sets. The scoring system was further validated successfully in nine additional HGSOC public datasets. In conclusion, our integrative bioinformatics study combining transcriptomic and clinical data established an 11-gene prognostic signature for robust and reproducible prediction of OS in HGSOC patients. This signature could be of clinical value for guiding therapeutic selection and individualized treatment.

show abstract

A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma

Cited by 5 publications

References 32 publications

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma

Identification of a 3‑mRNA signature as a novel potential prognostic biomarker in patients with ovarian serous cystadenocarcinoma in G2 and G3

A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer

Contact Info

Product

Resources

About